5N Plus Inc. (TSE:VNP – Get Free Report)’s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as C$19.60 and last traded at C$17.98, with a volume of 128688 shares trading hands. The stock had previously closed at C$17.66.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on VNP. National Bankshares upped their price target on 5N Plus from C$17.00 to C$21.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Cormark upgraded shares of 5N Plus from a “moderate buy” rating to a “strong-buy” rating in a research note on Thursday, September 25th. Ventum Financial raised their price target on shares of 5N Plus from C$11.00 to C$14.00 and gave the company a “buy” rating in a report on Thursday, July 24th. Finally, Desjardins lifted their price target on shares of 5N Plus from C$11.00 to C$14.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Strong Buy” and an average price target of C$16.33.
Check Out Our Latest Report on VNP
5N Plus Stock Performance
About 5N Plus
5N+ is a leading global producer of specialty semiconductors and performance materials. The Company’s ultra pure materials often form the core element of its customers’ products. These customers rely on 5N+’s products to enable performance and sustainability in their own products. 5N+ deploys a range of proprietary and proven technologies to develop and manufacture its products.
Further Reading
- Five stocks we like better than 5N Plus
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- 3 Defense Stocks Set to Benefit From Increased Military Spending
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for 5N Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 5N Plus and related companies with MarketBeat.com's FREE daily email newsletter.